News

Tuesday, August 30, 2016

CardioCell announces positive results from phase IIa study evaluating IV administration of stem cells for chronic HF indications

PB

CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announced data from its phase IIa clinical trial “Safety and Efficacy of Intravenous Infusion of Ischemia-Tolerant Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Cardiomyopathy” at the European Society of Cardiology (ESC) Congress. READ FULL ARTICLE